Canada: Canadian Competition Bureau Issues Draft Update Of Intellectual Property Enforcement Guidelines

Last Updated: June 15 2015
Article by Davit D. Akman, Francois Baril and Ian Macdonald

Most Read Contributor in Canada, October 2018

On June 9, 2015, the Canadian Competition Bureau issued a draft update of its Intellectual Property Enforcement Guidelines ("IPEGs") for public consultation (see here). The IPEGs describe the Bureau's approach to the interface between competition law and intellectual property rights, and its enforcement approach to conduct involving the exercise of IP rights.

The draft update sets out the Bureau's proposed enforcement approach in respect of the activities of patent assertion entities ("PAEs") (i.e., companies whose business model is asserting patents although they do not manufacture or sell products or services related to such patents), the settlement of patent litigation proceedings in the pharmaceutical industry and conduct involving standard essential patents ("SEPs") (i.e., a patent that claims an invention that must be used in order to conform to a standard adopted by a standard setting or development organization ("SDO")). 

The new draft update follows the publication by the Bureau in September 2014 of a stage 1 update of the IPEGs (which consisted primarily of administrative revisions to reflect amendments to the Canadian Competition Act, since the IPEGs were issued in September 2000) and a white paper setting out the Bureau's preliminary views as to how Canadian competition law could apply to pharmaceutical patent litigation settlements. The white paper gave rise to significant controversy in that (among other things) it proposed a vague enforcement policy under which the Bureau would, at the Commissioner of Competition's discretion, review pharmaceutical patent litigation settlements under the criminal conspiracy provision in section 45 of Act.

Conduct involving PAEs

The draft update addresses conduct involving PAEs only with respect to the "the sending of false and misleading claims." The update sets out the Bureau's position that the sending of thousands of litigation demand letters by a PAE to various businesses alleging that those businesses are infringing the PAE's patents and demanding the payment of a license fee to avoid litigation could attract scrutiny under the misleading advertising provisions of the Act. Those provisions include a general criminal prohibition against false or misleading representations (section 52) and a general civil prohibition against deceptive marketing practices (section 74.01). These prohibitions are substantially similar, except that liability under the criminal prohibition also requires proof that the representation was made "knowingly or recklessly." Both require a representation — made to the public — to promote a product, service, or business interest that is false or misleading in a material respect.

According to the draft update, where there is evidence that the firm sending the demand letters "was sending [those] letters to businesses indiscriminately, or was indifferent to whether the representations [as to the alleged infringement of its patents] were misleading, then the misrepresentations were made knowingly or recklessly and would raise concerns under both the reviewable matters and criminal provisions of the Act."

Violations of the Act's criminal misleading advertising provisions can attract serious consequences, including fines in the discretion of the court and/or up to 14 years imprisonment. The consequences of contravening the Act's civil deceptive marketing practices provisions may also be severe. Among other things, the Act provides for the imposition of an administrative monetary penalty of up to $10 million for a first offence, and a penalty of up to $15 million for each subsequent contravention of the Act.

Pharmaceutical patent litigation settlements

The draft update summarizes the Bureau's proposed enforcement approach to pharmaceutical patent litigation settlements as follows:

"i. An entry-split settlement ([i.e., 'a settlement [that] does not involve the brand-name company providing any consideration to the generic firm other than allowing the generic to enter the market before patent expiry']) pursuant to which the generic firm enters the market prior to patent expiry will not pose an issue under the Act...;

ii. A settlement with a payment ([i.e., 'compensation to the generic firm in addition to allowing generic market entry before patent expiry']) to the generic firm pursuant to which the generic firm enters the market prior to patent expiry will be reviewed under section 90.1 [...] or possibly section 79, except in the circumstances specified in (iii);

iii. A settlement may be reviewed under section 45 only where there is evidence that the intent of the payment was to fix prices, allocate markets or restrict output...."

In explaining the analytical framework underlying this approach, the draft update indicates that it is the Bureau's expectation "that in the vast majority of cases, the Bureau will review a settlement under section 90.1 of the Act because it would not be viewed as an agreement between competitors to fix prices, allocate markets or restrict output (i.e., a 'naked restraint' on competition)." Further, in the circumstances specified in (ii), above, the draft update states that the initial focus of the Bureau's review under section 90.1 (or under section 79) will be on the question of whether the payment was "for the purpose of delaying generic entry" and that if the Bureau finds that the payment in issue was within a reasonable estimate of (A) the fair market value of any goods or services provided by the generic firm; (B) the magnitude of the innovator company's section 8 damages exposure under the PMNOC regulations; and (C) the innovator company's expected remaining litigation costs absent settlement,1 "the Bureau would likely conclude that the settlement does not raise issues under the Act." 

In circumstances where the Bureau concludes that the magnitude of the payment was so large that it was "probably for the purpose of delaying entry", the draft update indicates that in assessing whether the settlement substantially prevented or lessened competition, the Bureau would then consider the competitive effects of the delayed entry, as well as possible efficiency gains from the settlement (in the case of a review under section 90.1) or possible business justifications (in the case of a review under section 79) before deciding whether to seek a remedy from the Competition Tribunal. Under section 90.1, the only available remedy is an order prohibiting the settlement. Under section 79 of the Act, the potential remedies include a prohibition order and administrative monetary penalties of up to $10 million (or of up to $15 million in the case of a second or subsequent contravention of that provision).

With respect to the possibility of criminal review, the draft update indicates that the "limited circumstances" in which a settlement may be reviewed under the criminal conspiracy provision in section 45 include where the settlement provides for generic entry after patent expiry and where there is "convincing documentary evidence that both parties recognized that the patent was not valid".

Conduct involving SEPs

The draft update indicates that the activities of SDOs raise competition risks (including potential criminal prosecution under section 45 of the Act) insofar as discussions among competitors in the standard-setting process may lead to agreements to fix the price of goods or services or "naked agreements on licensing terms", or may "facilitate joint discussions among members of licensing terms and conditions".

With respect to so-called "patent hold-up" and "patent ambush", the draft update indicates that a failure to disclose patents essential to a standard coupled with subsequent infringement litigation in respect of the previously undisclosed patents against those implementing the standard could attract antitrust liability under the abuse of dominance provision in section 79 of the Act. So too could breaches by an SEP owner of a voluntary commitment to license on fair, reasonable and non-discriminatory ("FRAND") terms, including the transfer of the patent subject to a licensing commitment to another firm which does not abide by the commitment given by the previous patent owner.

On the question of whether competition law imposes any limits on the right of owners of FRAND-encumbered SEPs to seek injunctive relief when their patents are allegedly infringed by implementers, the draft update states the Bureau's position that it may be appropriate for the SEP owner who has made a licensing commitment to seek injunctive relief "in certain circumstances," including "when a prospective licensee refuses to pay a royalty that is determined to be FRAND by a court or arbitrator, or when the prospective licensee does not engage in licensing negotiations." The draft update indicates that outside of these (and other unidentified) circumstances, the Bureau would likely review the seeking of injunctive relief by the holder of a FRAND-encumbered SEP as a potential abuse of dominance under section 79.

Conclusion

Once finalized, the draft update will define the Bureau's enforcement approach to a number of important and novel (at least in Canada) issues at the intersection of IP and competition law for many years to come. Companies that stand to be affected by the new enforcement guidelines and other stakeholders should give serious consideration to participating in the public consultation process.

The deadline for submitting comments to the Bureau is August 10, 2015. 


Footnote

1 With respect to the innovator company's expected remaining litigation costs, the draft update clarifies that "... expected remaining litigation costs absent settlement may include the expected costs of a subsequent patent infringement action and impeachment counterclaim, and potential adverse cost awards at both the prohibition application stage and in an infringement/impeachment proceeding."

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions